1991-2006

In 1991, along with the regaining of Latvian national independence, the Latvian State medicinal drug research and manufacturing company «Grindeks» was founded on the basis of the Experimental Plant. The name of the company emanates from the name of the first pharmacist, natural scientist, doctor and Professor of Chemistry of Latvian origin, Dāvids Hieronīms Grindelis.

In 1997, the company’s privatisation process is concluded and the Public Joint Stock Company «Grindeks» was established. During the course of the privatisation process, «Grindeks» attracted more than 6,000 shareholders. In March 1998, Public Joint Stock Company «Grindeks» acquired a majority shareholding in the Tallinn Pharmaceutical Plant (55%). The quotation of «Grindeks» shares on the Riga Stock Exchange commenced on June 1, 1998.

In 2000, «Grindeks» received the Good Manufacturing Practice (GMP) certificate issued by the United Kingdom’s Medicine Control Agency. The receipt of this certificate certifies the compliance of the company’s tablet and capsule plant to the international requirements of pharmaceutical manufacturing.

During 2001, «Grindeks» implements the principles of the ISO 9001:2000 quality standard. In September, the company received the International Environment Authority’s ISO 14001:1996 certificate and in November, the US Food and Drug Administration recognised the compliance of the manufacturing and control of the active ingredient oxitocine to international standards.

In caring for the protection of the surrounding environment and work safety, in 2002 the company signed up to the UN Global Compact and the global chemical industry’s Responsible Care programme.

On March 12, 2003, investments and systematic work on the modernisation and further development of the company allowed «Grindeks» to become the first in-house pharmaceutical manufacturer to receive the Good Manufacturing Practice Certificate from the Latvian State Agency of Medicines. With this certificate, the State has recognised that the quality of products manufactured by «Grindeks» conforms to global standards.

In 2005, JSC «Grindeks» is on its way to becoming the first pharmaceutical concern in the Baltic States.